LucenceLONGEVITY is a combination of our LucenceINSIGHT 50 and CardioHemeRISK tests.
LucenceINSIGHT 50 is a multi-cancer early detection (MCED) next-generation sequencing (NGS) blood test that screens for 50 cancers with 99% specificity (low false-positives). The test uses Lucence's mirror barcoding technology to detect ctDNA, ctRNA, and viral DNA. It can then predict tumor location with machine learning.
CardioHemeRISK is a next-generation sequencing (NGS) blood test. The test detects clonal hematopoiesis (CH) mutations to assess the risk of developing heart attack, stroke and leukemia.
Available internationally outside the USA.
What is CH?
Clonal hematopoiesis (CH) is a common disorder acquired as a age- and lifestyle- related inflammatory process.
It starts typically above age 40 when one blood stem cell develops a mutation and begins making lots of blood cells (clonal expansion) with the same mutation. It is not cancer.
.png)
What is ctDNA and ctRNA?
ctDNA is shed by dying cancer cells while ctRNA is actively released by living cancer cells [1]. In the early-stage, cancer cells are often intact and viable making ctRNA a valuable biomarker for early detection [2], [3].
References:
-
Stejskal P, et al. Mol Cancer 2023; 22(15).
-
Ju C-W, et al. Nat. Biotechnol. 2025; https://doi.org/10.1038/s41587-025-02731-8.
-
Ambrosi S, et al. Int. J. Mol. Sci. 2023; 24(5): 4881
